Little Green Pharma Ltd (ASX: LGP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Little Green Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$29.06 million
P/E Ratio
5.64
Dividend Yield
0.00%
Shares Outstanding
305.65 million
Earnings per share
0.020
Dividend per share
N/A
Year To Date Return
-23.20%
Earnings Yield
17.73%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Little Green Pharma Ltd (ASX: LGP)
Latest News
Cannabis Shares
Why did this ASX cannabis share just rocket 46%?
Cannabis Shares
Why are these 2 ASX cannabis shares booming all of a sudden?
Cannabis Shares
Little Pharma shares lift 8% amid appointment of 'highly regarded' director
Cannabis Shares
Why did the Little Green Pharma share price flame 23% higher today?
Cannabis Shares
ASX cannabis shares in spotlight amid COVID prevention research
Share Gainers
Why is the Little Green Pharma (ASX:LGP) share price in the green today?
Cannabis Shares
Little Green Pharma (ASX:LGP) share price leaps 7% on revenue growth
Healthcare Shares
How did ASX healthcare shares perform in the FY22 first quarter?
Cannabis Shares
Little Green Pharma (ASX:LGP) share price lifts as bosses reflect on a big year
Cannabis Shares
The Little Green Pharma (ASX:LGP) share price has fallen 7% this month
Share Market News
What's going wrong for ASX cannabis shares lately?
Share Market News
Why the Little Green Pharma (ASX:LGP) share price has lost 20% since July
LGP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Little Green Pharma Ltd
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets.
LGP Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Mar 2026 | $0.10 | $0.00 | 0.00% | 148,684 | $0.10 | $0.11 | $0.09 |
| 18 Mar 2026 | $0.10 | $0.00 | 0.00% | 309,250 | $0.10 | $0.11 | $0.10 |
| 17 Mar 2026 | $0.10 | $0.00 | 0.00% | 77,340 | $0.11 | $0.11 | $0.10 |
| 16 Mar 2026 | $0.10 | $0.00 | 0.00% | 80,623 | $0.11 | $0.11 | $0.10 |
| 13 Mar 2026 | $0.11 | $-0.01 | -8.70% | 50,532 | $0.12 | $0.12 | $0.11 |
| 12 Mar 2026 | $0.12 | $0.01 | 9.09% | 59,405 | $0.11 | $0.12 | $0.11 |
| 11 Mar 2026 | $0.11 | $0.01 | 10.00% | 94,722 | $0.11 | $0.12 | $0.10 |
| 10 Mar 2026 | $0.10 | $0.00 | 0.00% | 157,854 | $0.10 | $0.11 | $0.10 |
| 09 Mar 2026 | $0.10 | $-0.01 | -9.09% | 494,063 | $0.12 | $0.12 | $0.10 |
| 06 Mar 2026 | $0.11 | $0.00 | 0.00% | 151,768 | $0.11 | $0.11 | $0.11 |
| 05 Mar 2026 | $0.11 | $0.00 | 0.00% | 66,383 | $0.11 | $0.11 | $0.11 |
| 04 Mar 2026 | $0.11 | $0.00 | 0.00% | 170,206 | $0.11 | $0.12 | $0.11 |
| 03 Mar 2026 | $0.11 | $0.00 | 0.00% | 37,176 | $0.11 | $0.11 | $0.11 |
| 02 Mar 2026 | $0.11 | $0.01 | 9.52% | 81,714 | $0.11 | $0.12 | $0.11 |
| 27 Feb 2026 | $0.11 | $-0.01 | -9.09% | 164,054 | $0.11 | $0.12 | $0.11 |
| 26 Feb 2026 | $0.11 | $0.00 | 0.00% | 13,167 | $0.12 | $0.12 | $0.11 |
| 25 Feb 2026 | $0.11 | $-0.01 | -8.70% | 255,813 | $0.12 | $0.12 | $0.11 |
| 24 Feb 2026 | $0.12 | $0.00 | 0.00% | 65,913 | $0.12 | $0.12 | $0.12 |
| 23 Feb 2026 | $0.12 | $0.00 | 0.00% | 450,680 | $0.12 | $0.12 | $0.11 |
| 20 Feb 2026 | $0.12 | $0.00 | 0.00% | 92,423 | $0.12 | $0.12 | $0.12 |
| 19 Feb 2026 | $0.12 | $0.01 | 9.09% | 137,864 | $0.12 | $0.12 | $0.11 |
| 18 Feb 2026 | $0.11 | $-0.01 | -8.70% | 473,764 | $0.12 | $0.12 | $0.11 |
| 17 Feb 2026 | $0.12 | $0.00 | 0.00% | 34,681 | $0.12 | $0.12 | $0.12 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Feb 2026 | Neale Fong | Exercise | 70,000 | $7,700 |
Conversion of securities. 150,000 rights
|
| 26 Feb 2026 | Neale Fong | Buy | 70,000 | $7,700 |
Conversion of securities.
|
| 26 Feb 2026 | Michael Lynch-Bell | Exercise | 140,000 | $15,400 |
Conversion of securities. 300,000 rights
|
| 26 Feb 2026 | Michael Lynch-Bell | Buy | 140,000 | $15,400 |
Conversion of securities.
|
| 01 Sep 2025 | Paul Long | Issued | 2,000,000 | $260,000 |
Issue of options.
|
| 01 Sep 2025 | Angus Caithness | Issued | 2,000,000 | $260,000 |
Issue of options.
|
| 01 Sep 2025 | Fleta Solomon | Issued | 1,200,000 | $156,000 |
Issue of options.
|
| 15 Jul 2025 | Michael Lynch-Bell | Issued | 70,000 | $7,350 |
Conversion of securities.
|
| 15 Jul 2025 | Michael Lynch-Bell | Exercise | 70,000 | $7,350 |
Conversion of securities. 440000 Rights, as per announcement on 22-07-2025
|
| 15 Jul 2025 | Neale Fong | Issued | 35,000 | $3,675 |
Conversion of securities.
|
| 15 Jul 2025 | Neale Fong | Exercise | 35,000 | $3,675 |
Conversion of securities. 220000 Rights, as per announcement on 22-07-2025
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Neale William Fong | Non-Executive Director | Nov 2018 |
Ms Fong has over 36 years in senior leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organizations. Neale is currently CEO of Bethesda Health Care and formerly was Director General of the West Australian Department of Health. She is Chair of the Risk Committee.
|
| Mr Angus McDougall Caithness | Executive Director | Feb 2018 |
Mr Caithness is a corporate finance executive and consultant in Australia and international markets. Following these roles, Angus acted as CFO of Erdenes Tavan Tolgoi, the owner of a coking coal deposit looking at a US$10 billion dual listing in London and Hong Kong prior to the change in the Mongolian government. Prior to that he was an Executive Director at EY in London and Australia specializing in initial public offerings of large-cap mining companies.
|
| Ms Fleta Jennifer Solomon | Executive Director | May 2017 |
Ms Solomon was a founder of Little Green Pharma and grew the company from a medicinal cannabis startup to an industry leading medicinal cannabis brand in Australia and overseas. Fleta has 20 years of experience in corporate and consumer health markets.
|
| Mr Michael David Lynch-Bell | Non-Executive ChairmanNon-Executive Director | Nov 2018 |
Mr Lynch-Bell is a corporate finance executive and consultant. His early Ernst & Young career was focused on auditing clients within the oil and gas sectors and later added mining to his portfolio. He also led Ernst & Young's UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice. He has been involved advising companies on fundraising, reorganizations, transactions, corporate governance as well as IPOs. He is a former Chair of the Bureau and current member of UNECE's Expert Group on Resource Management. He is member of Risk Committee
|
| Mr Paul Long | Chief Executive OfficerManaging Director | Aug 2023 |
Mr Long is an executive with over two decades of experience across the health, pharmaceutical, and medicinal cannabis industries. Paul transitioned into consultancy, advising a range of enterprise health, health tech, and retail pharmaceutical businesses. Since stepping into the role of Chief Executive Officer and now Managing Director, Paul has continued to drive strong performance and long-term growth. Paul also oversaw the doubling of revenue in Europe, supported by the expansion of LGP's Danish facility, and led the integration of the Health House acquisition.
|
| Mr Alistair Warren | Company Secretary | Jul 2020 |
-
|
| Alistair Warren | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| UBS Nominees Pty Ltd | 57,078,524 | 18.82% |
| Ms Fleta Jennifer Solomon | 20,723,216 | 6.83% |
| Barbright Australia Pty Ltd <Interquartz Super A/C> | 13,732,793 | 4.53% |
| Benoni Pty Ltd <The Mkj Super Fund A/C> | 8,847,285 | 2.92% |
| BNP Paribas Nominees Pty Ltd ACF CLEARSTREAM | 7,334,936 | 2.42% |
| Mr Angus Caithness | 5,751,441 | 1.90% |
| HSBC Custody Nominees (Australia) Limited | 5,649,133 | 1.86% |
| Banquo Consulting Pty Ltd | 5,413,333 | 1.78% |
| CG Nominees (Australia) Pty Ltd | 4,147,061 | 1.37% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 4,049,454 | 1.33% |
| Jasforce Pty Ltd | 2,883,878 | 0.95% |
| Citicorp Nominees Pty Limited | 2,714,517 | 0.89% |
| Mr Paul Frederick Long <The Long A/C> | 2,426,191 | 0.80% |
| Ms Jenny Lorraine Mckay <J & K Mckay Family A/C> | 2,229,746 | 0.74% |
| Ms Rhianna Louise Belcham | 2,100,000 | 0.69% |
| Mr Damien Matthew Booth <Damien Booth Family A/C> | 1,858,639 | 0.61% |
| Mr Michael David Lynch Bell | 1,758,450 | 0.58% |
| Nurturing Evolutionary Development Pty Ltd | 1,708,000 | 0.56% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 1,636,358 | 0.54% |
| Assert Corporate & Investor Relations Pty Ltd Chapter One Advisors> | 1,556,821 | 0.51% |